These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 19460067)

  • 21. Costs and effects of long-acting risperidone compared with oral atypical and conventional depot formulations in Germany.
    Laux G; Heeg B; van Hout BA; Mehnert A
    Pharmacoeconomics; 2005; 23 Suppl 1():49-61. PubMed ID: 16416761
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness and quality of life in psychosis: the pharmacoeconomics of risperidone.
    Aronson SM
    Clin Ther; 1997; 19(1):139-47; discussion 126-7. PubMed ID: 9083716
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cost analysis of the treatment of schizophrenia in the UK. A simulation model comparing olanzapine, risperidone and haloperidol.
    Almond S; O'Donnell O
    Pharmacoeconomics; 2000 Apr; 17(4):383-9. PubMed ID: 10947493
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Atypical antipsychotics for disruptive behaviour disorders in children and youths.
    Loy JH; Merry SN; Hetrick SE; Stasiak K
    Cochrane Database Syst Rev; 2017 Aug; 8(8):CD008559. PubMed ID: 28791693
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cost-benefits of risperidone.
    Bilsker D
    Psychiatr Serv; 1996 Mar; 47(3):309-10. PubMed ID: 8820560
    [No Abstract]   [Full Text] [Related]  

  • 26. A cost-effectiveness clinical decision analysis model for schizophrenia.
    Palmer CS; Revicki DA; Genduso LA; Hamilton SH; Brown RE
    Am J Manag Care; 1998 Mar; 4(3):345-55. PubMed ID: 10178497
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Maintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on Schizophrenia.
    Gaebel W; Riesbeck M; Wölwer W; Klimke A; Eickhoff M; von Wilmsdorff M; Jockers-Scherübl MC; Kühn KU; Lemke M; Bechdolf A; Bender S; Degner D; Schlösser R; Schmidt LG; Schmitt A; Jäger M; Buchkremer G; Falkai P; Klingberg S; Köpcke W; Maier W; Häfner H; Ohmann C; Salize HJ; Schneider F; Möller HJ;
    J Clin Psychiatry; 2007 Nov; 68(11):1763-74. PubMed ID: 18052570
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Olanzapine vs. risperidone in treating aggressive behaviours in adults with intellectual disability: a single blind study.
    Amore M; Bertelli M; Villani D; Tamborini S; Rossi M
    J Intellect Disabil Res; 2011 Feb; 55(2):210-8. PubMed ID: 21129058
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Risperidone. A pharmacoeconomic review of its use in schizophrenia.
    Foster RH; Goa KL
    Pharmacoeconomics; 1998 Jul; 14(1):97-133. PubMed ID: 10182198
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Impact of newer antipsychotics on outcomes in schizophrenia.
    Keks NA
    Clin Ther; 1997; 19(1):148-58; discussion 126-7. PubMed ID: 9083717
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Antipsychotic drugs for aggression in intellectual disability.
    Matson JL; Wilkins J
    Lancet; 2008 Jan; 371(9606):9-10. PubMed ID: 18177758
    [No Abstract]   [Full Text] [Related]  

  • 32. Positive behaviour support training for staff for treating challenging behaviour in people with intellectual disabilities: a cluster RCT.
    Hassiotis A; Poppe M; Strydom A; Vickerstaff V; Hall I; Crabtree J; Omar R; King M; Hunter R; Bosco A; Biswas A; Ratti V; Blickwedel J; Cooper V; Howie W; Crawford M
    Health Technol Assess; 2018 Mar; 22(15):1-110. PubMed ID: 29596045
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacoeconomics of depot antipsychotics for treating chronic schizophrenia in Sweden.
    Einarson TR; Vicente C; Zilbershtein R; Piwko C; Bø CN; Pudas H; Jensen R; Hemels ME
    Nord J Psychiatry; 2014 Aug; 68(6):416-27. PubMed ID: 24274837
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial.
    Rosenheck R; Perlick D; Bingham S; Liu-Mares W; Collins J; Warren S; Leslie D; Allan E; Campbell EC; Caroff S; Corwin J; Davis L; Douyon R; Dunn L; Evans D; Frecska E; Grabowski J; Graeber D; Herz L; Kwon K; Lawson W; Mena F; Sheikh J; Smelson D; Smith-Gamble V;
    JAMA; 2003 Nov; 290(20):2693-702. PubMed ID: 14645311
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Atypical antipsychotic medication improves aggression, but not self-injurious behaviour, in adults with intellectual disabilities.
    Ruedrich SL; Swales TP; Rossvanes C; Diana L; Arkadiev V; Lim K
    J Intellect Disabil Res; 2008 Feb; 52(Pt 2):132-40. PubMed ID: 18197952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Risperidone for aggression and self-injurious behavior in adults with mental retardation.
    Cohen SA; Ihrig K; Lott RS; Kerrick JM
    J Autism Dev Disord; 1998 Jun; 28(3):229-33. PubMed ID: 9656134
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Possibilities and limits of treatment of aggressive behavior in patients with mental retardation with risperidone].
    Hässler F; Buchmann J; Bohne S
    Nervenarzt; 2002 Mar; 73(3):278-82. PubMed ID: 11963264
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Economic consequences of the adverse reactions related with antipsychotics: an economic model comparing tolerability of ziprasidone, olanzapine, risperidone, and haloperidol in Spain.
    Bobes J; Cañas F; Rejas J; Mackell J
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Dec; 28(8):1287-97. PubMed ID: 15588755
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Is risperidone effective in reducing challenging behaviours in individuals with intellectual disabilities after 1 year or longer use? A placebo-controlled, randomised, double-blind discontinuation study.
    Ramerman L; de Kuijper G; Scheers T; Vink M; Vrijmoeth P; Hoekstra PJ
    J Intellect Disabil Res; 2019 May; 63(5):418-428. PubMed ID: 30609152
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.